Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common Shares, without par value
-
Shares outstanding
-
8,333,333
-
Total 13F shares
-
207,513
-
Share change
-
+46,165
-
Total reported value
-
$350,110
-
Price per share
-
$1.68
-
Number of holders
-
16
-
Value change
-
+$46,292
-
Number of buys
-
6
-
Number of sells
-
6
Institutional Holders of Edesa Biotech, Inc. - Common Shares, without par value (EDSA) as of Q4 2024
As of 31 Dec 2024,
Edesa Biotech, Inc. - Common Shares, without par value (EDSA) was held by
16 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
207,513 shares.
The largest 10 holders included
CM Management, LLC, CITADEL ADVISORS LLC, GEODE CAPITAL MANAGEMENT, LLC, VANGUARD GROUP INC, TWO SIGMA SECURITIES, LLC, Tower Research Capital LLC (TRC), Royal Bank of Canada, TD Waterhouse Canada Inc., FIFTH THIRD BANCORP, and UBS Group AG.
This page lists
16
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.